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Abstract: Telavancin is a novel antibiotic being investigated for the treatment of serious 
infections caused by Gram-positive bacteria, including complicated skin and skin structure 
infections (cSSSI) and pneumonia. This once-daily intravenous lipoglycopeptide exerts rapid 
bactericidal activity via a dual mechanism of action. It is intended for use to combat infections 
caused by Staphylococcus aureus and other Gram-positive bacteria, including methicillin-
resistant and vancomycin-intermediate strains of S. aureus (MRSA and VISA, respectively). 
Vancomycin is the current gold standard in treating serious infections caused by Gram-positive 
bacteria, especially MRSA. In recent clinical trials, telavancin has shown excellent efﬁ  cacy in 
phase II and III multinational, randomized, double-blinded studies of cSSSI. In the phase II 
FAST 2 study, which compared telavancin 10 mg/kg intravenously q 24 h vs standard therapy 
(an antistaphylococcal penicillin at 2 g IV q 6 h or vancomycin 1 gm IV q 12 h), the clinical 
success rate in the telavancin-treated group was 96% vs 94% in the standard therapy group. In 
two identical phase III trials comparing telavancin versus vancomycin at the doses of the FAST 
2 study for cSSSI, the clinical cure rates were 88.3% and 87.1%, respectively. Two additional 
phase III clinical trials investigating telavancin for use in hospital-acquired pneumonia, caused 
by Gram-positive bacteria are currently ongoing. Telavancin is currently under regulatory review 
in both the United States and Europe for the indication of treatment of cSSSI.
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Introduction
In 1928, Sir Alexander Fleming’s discovery and isolation of penicillin from the 
penicillium mold marked the beginning of modern antibiotics. By the early 1940s, 
Pﬁ  zer had developed a deep-tank fermentation method to produce mass quantities of 
penicillin for pharmaceutical use (Pﬁ  zer 2007). This “miracle drug” has since become 
the most widely used antibiotic to date and it is active against many Gram-positive 
bacteria. Universal sensitivity of common Gram-positive bacteria to penicillin was, 
however short lived. By 1945, resistance to penicillin mediated by β-lactamase 
production was reported in isolates of Staphylococcus aureus, one of the most 
common and virulent Gram-positive bacteria encountered clinically (Spink and 
Ferris 1945). In 1950, 40% of hospital S. aureus isolates were penicillin-resistant, 
and by 1960, this proportion had increased to 80% (Chambers 2001). Consequently, 
penicillin is no longer a consideration in the empiric management of infections likely 
to be caused by S. aureus. This pathogen causes serious invasive infections, such as 
community acquired and nosocomial pneumonia, endocarditis, soft tissue infections, 
and bacteremia (Drew 2007).
Initial S. aureus resistance was mediated by bacterial production of β-lactamase or 
penicillinase enzymes that could cleave the β-lactam ring structure of the antibiotic, 
rendering it ineffective. As a result, β-lactam antibiotics, such as methicillin, cloxacillin, 
and oxacillin, were developed with modiﬁ  cation of the chemical structure that protected Therapeutics and Clinical Risk Management 2008:4(1) 236
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the β-lactam ring from cleavage by the β-lactamase enzymes. 
These antibiotics soon became the mainstay of empiric 
treatment for infections thought to be caused by S. aureus. 
Introduced in 1959, methicillin was the ﬁ  rst antibiotic of the 
class to be used, but by 1961, the ﬁ  rst case of methicillin-
resistant S. aureus (MRSA) was documented during routine 
screening of hospital isolates at a reference laboratory in 
England (Jevons 1961).
To compound matters, a growing medical concern has 
been the emergence of multidrug-resistant strains among 
isolates of S. aureus (Goossens 2006). In the 1990s, hospital-
acquired MRSA (HA-MRSA), which had generally remained 
uncommon, suddenly surged in prevalence and is now 
endemic in this setting (Johnson et al 2001). In 2006, results 
of the Surveillance Network USA showed that nearly 60% of 
hospital-derived S. aureus isolates were MRSA (Styers et al 
2006). One of the most disturbing features of HA-MRSA 
is its multi-drug resistance, including resistance to all the 
β-lactam antibiotics, penems and carbapenems. Resistance 
to multiple other antibiotic classes including aminoglyco-
sides, macrolides, and tetracyclines, as well as the antibiotic 
trimethoprim is common through plasmid mediated transfer 
of resistance (Swartz 1994). Point mutations on DNA gyrase 
and topoisomerase IV, and hyperexpression of efﬂ  ux pump 
proteins accounted for the rapid resistance of HA-MRSA 
to flouroquinolones shortly after their widespread use 
(Hershow et al 1998; Hooper 1999). In the early 2000s, a 
new strain of community-acquired MRSA (CA-MRSA) was 
identiﬁ  ed in infections acquired in the community setting 
in patients who had no identiﬁ  able risk factors for the HA 
strain. Resistance in CA-MRSA is also mediated through 
acquisition and expression of PBP-2a, which provides resis-
tance to methicillin, but unlike the hospital-acquired strain, 
CA-MRSA presently remains highly sensitive to clindamy-
cin, rifampin, and trimethoprim-sulfamethoxazole, and the 
tetracyclines (Moran et al 2006). CA-MRSA differs from the 
early HA strains (now broadened to healthcare-associated 
(HCA)) by being more strongly associated with a virulence 
factor, the Panton-Valentine Leukocidin (PVL) toxin, which 
seems to be responsible for its invasiveness and necrotizing 
properties (Davis et al 2007). Failure to inhibit production 
of PVL may play a signiﬁ  cant role in outcome of serious 
necrotizing infections and will likely impact the choice of 
antibiotics used. Findings from a prospective surveillance 
study conducted in 11 emergency departments across the 
US has helped to characterize the etiology of complicated 
skin and skin structure infections (cSSSIs) (Moran et al 
2006). S. aureus was isolated from the infection site in 320 
of 422 patients (76%). Furthermore, the overall prevalence 
of MRSA was 59% nearly all of which had pulsed-ﬁ  eld 
types characteristic of CA-MRSA. Genes encoding pvl were 
contained within 98% of MRSA isolates and 40% of MSSA 
isolates. Other bacterial pathogens such as Streptococcus spp. 
(7%), coagulase-negative staphylococci (3%) and Proteus 
mirabilis (1%) were identiﬁ  ed as a small but signiﬁ  cant cause 
of cSSSI in this study. For this reason, these purulent infec-
tions were commonly treated with non-β-lactam antibiotics, 
such as clindamycin and trimethoprim-sulfamethoxazole 
(Moran et al 2006). Results from another well conducted 
prospective epidemiologic study found lower rates of PVL 
expression among S. aureus, although 54% of CA-MRSA 
isolates (n = 102) and 10% of MSSA isolates (n = 102) still 
carried pvl genes (Davis et al 2007). Overall, these micro-
biological data highlight important knowledge deﬁ  cits and/or 
the dynamic environment surrounding the epidemiology and 
causes of cSSSIs.
In an article from the Infectious Disease Society of 
America written in 2006 (Talbot et al 2006) entitled “Bad 
Bugs, Need Drugs”, the dilemma of treating emerging 
resistant organisms and the dearth of new antibiotics in 
development was highlighted. In response to this need, 
several new antibiotics have recently been approved and are 
currently in use to treat serious infections caused by resistant 
strains of S. aureus. This list includes: linezolid, tigecycline, 
and daptomycin. There are a number of other agents in various 
stages of development and regulatory review such as the 
lipoglycopeptides telavancin, oritavancin, and dalbavancin, 
as well as agents from traditional antimicrobial drug classes 
(eg, the cephalosporins, ceftobiprole, and ceftaroline, and 
the trimethoprim congener iclaprim).
Currently, glycopeptide antibiotics such as vancomycin 
and teicoplanin are the gold standard for the treatment 
of serious invasive infections due to MRSA (although 
teicoplanin is not approved for use in the United States) (Van 
Bambeke 2004; Rice 2006). Vancomycin, available since 
1950, is presently considered to be the preferred treatment 
for invasive infections caused by MRSA. This is in part due 
to its favorable safety proﬁ  le as well as extensive published 
studies documenting its utility in the treatment of serious 
invasive infections (Drew 2007).
The utility of vancomycin is, however, compromised by 
several important factors. These include: (1) poor penetration 
of the antibiotic into infected tissues in the lungs, brain, 
and meninges, which has been associated with unfavorable 
treatment outcomes in serious infections such as pneumonia, 
endocarditis and meningitis (Levine 2006; Stevens 2006; Therapeutics and Clinical Risk Management 2008:4(1) 237
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Drew 2007); (2) an adverse effect of bioﬁ  lms produced by 
several S. aureus strains on vancomycin’s microbiologic 
activity (Nishimura et al 2006; Sakoulas et al 2006; Drew 
2007); and (3) emergence of resistance to vancomycin 
in enterococci and staphylococci (Moellering 2006). The 
ﬁ  rst vancomycin-intermediate S. aureus (VISA) isolate 
was reported in Japan in 1996 (Hiramatsu et al 1997). 
Subsequently 2 cases of vancomycin-resistant S. aureus 
(VRSA) were ﬁ  rst reported in the United States in 2002 
(CDC 2002a, b). It is increasingly recognized that many 
S. aureus cultures are ‘heteroresistant’ (hVISA) containing a 
subpopulation of resistant organisms which survive antibiotic 
therapy (Maor et al 2007). Overall there has been an increase 
in the MICs of vancomycin against MRSA, associated with 
poorer outcomes, which has prompted the Clinical and 
Laboratory Standards Institute (CLSI) to lower vancomycin’s 
breakpoint from  4 µg/mL to  2 µg/mL for susceptible 
strains, from 8–16 µg/mL to 4–8 µg/mL for intermediately-
susceptible strains, and from  32 µg/mL to  16 µg/mL 
for resistant strains (CLSI 2007).
The emergence and prevalence of multidrug-resistant 
Gram-positive pathogens, as well as their increasing con-
tribution to nosocomial and serious community acquired 
infections, has prompted the development of several new 
antimicrobials. This review focuses on telavancin, and gives 
a general summary of the most recent published data.
Chemistry
Telavancin is a lipoglycopeptide, structurally similar 
to vancomycin (Figure 1). It has the same glycopeptide 
core as vancomycin, but has an added lipophilic side 
chain (decylaminoethyl) and a negatively charged group 
(phosphonomethyl aminomethyl). The lipophilic side chain 
has been hypothesized to enhance telavancin’s membrane-
anchoring properties leading to enhanced affinity for 
lipid II (Beauregard et al 1995; Leadbetter et al 2004; 
Laohavaleeson et al 2007). The polar moiety compensates 
for the prolonging effect of the lipophilic tail on elimination 
half-life by endowing the molecule with a partition coefﬁ  cient 
that ensures desirable absorption, distribution, metabolism, 
and renal excretion properties (Judice and Pace 2003; 
Leadbetter et al 2004; Laohavaleeson et al 2007).
Mechanism of action
Telavancin is a concentration-dependent, rapidly bactericidal 
antibiotic which has potent activity against clinically important 
Gram-positive pathogens such as staphylococci (including 
MRSA, hVISA, and VISA strains) and streptococci, 
(including penicillin-resistant Staphylococcus pneumoniae 
PRSP) as well as Gram-positive anaerobic and fastidious 
aerobic bacteria. Telavancin activity is mediated by multiple 
modes of action. In a mechanism shared with vancomycin, 
telavancin inhibits bacterial cell wall synthesis through 
tight binding of the aglycone core structure to D-alanine-
D-alanine-containing peptidoglycan precursor, lipid II, and 
nascent noncrosslinked peptidoglycan intermediates, thus 
inhibiting late stages of cell wall biosynthesis (Higgins et al 
2005). Telavancin is approximately 10-fold more potent than 
vancomycin in the inhibition of peptidoglycan synthesis. 
Additionally, in mechanisms not shared with vancomycin, 
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Figure 1 Chemical structures of vancomycin (left) and telavancin (right). Telavancin, structurally related to vancomycin, possesses a lipophilic side chain (decylaminoethyl, 
highlighted in red) and a negatively charged group (phosphonomethyl aminomethyl, highlighted in green).Therapeutics and Clinical Risk Management 2008:4(1) 238
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telavancin interacts with the Gram-positive bacterial 
membrane to effect changes in membrane potential and 
permeability in a concentration-dependent manner (Higgins 
et al 2005). A strong correlation was observed between 
the bactericidal activity of telavancin and these membrane 
effects. Parallel control experiments using vancomycin in 
this experimental system showed no effect on membrane 
potential or cell viability at 60 minutes. Overall, this dual 
multimodal mechanism of action of telavancin thus appears 
to be responsible for its enhanced in vitro potency and rapid 
bactericidal activity against most Gram-positive bacteria 
(Laohavaleeson et al 2007).
In vitro spectrum of activity
Telavancin is active against both vancomycin-susceptible and 
some vancomycin-resistant Gram-positive organisms. MIC 
Table 1 In vitro activities of telavancin and comparators against key Gram-positive bacteria. Data taken from surveillance studies 
evaluating clinical isolates
Antibacterial/organism 
(no. of isolates)a
MIC range (µg/ml) MIC90 range
(µg/ml)
% Susceptibleb References
Staphylococcus aureus: methicillin susceptible (n = 2 515)
Telavancin  0.015−1 0.25−0.5 NA (Draghi et al 2006; Sahm 
et al 2006; Jansen et al 
2007)
Vancomycin  0.25−2 1 100
Linezolid  0.5− 4 2 99.8−100
Daptomycin  0.03− 1 0.5 99.9
Staphylococcus aureus: methicillin resistant (n = 1 669)
Telavancin 0.06−1 0.25−0.5 NA (Draghi et al 2006; Sahm 
et al 2006; Jansen et al 
2007)
Vancomycin 0.5−41 −2 100
Linezolid  0.5− 4 2 99.4−99.8
Daptomycin 0.12− 1 0.5−1 99.6−99.7
Staphylococcus aureus: glycopeptide intermediate susceptible (n = 50)
Telavancin 0.125–1 1 NA (Leuthner et al 2006)
Vancomycin 4−8 8N R
Linezolid 0.5−4 2N R
Daptomycin 0.25−2 1N R
Streptococcus pneumoniae: penicillin susceptible (n = 371)
Telavancin  0.001–0.06 0.03 NA (Draghi et al 2006; 
Thornsberry et al 2006; 
Jansen et al 2007)
Vancomycin  0.06−1 0.5 100
Linezolid 0.25−2 1 100
Daptomycin  0.03−1 0.25 NA
Streptococcus pneumoniae: penicillin resistant (n = 74)
Telavancin 0.008−0.03 0.015−0.03 NA (Draghi et al 2006; 
Thornsberry et al 2006; 
Jansen et al 2007)
Vancomycin 0.25−0.5 0.5 100
Linezolid 0.5−1 1 100
Daptomycin 0.06−0.5 0.12−0.25 NA
Enterococcus faecalis: vancomycin susceptible (n = 928)
Telavancin 0.06−4 0.5−1 NA (Draghi et al 2005; Sahm 
et al 2006; Jansen et al 
2007)
Vancomycin  0.5−4 2 100
Linezolid 0.25−32 2 99.8−100
Daptomycin  0.015−4 1−2 100
Enterococcus faecalis: vancomycin nonsusceptible (n = 60)
Telavancin 0.25−16 8−16 NA (Draghi et al 2006; Sahm 
et al 2006; Jansen et al 
2007)
Vancomycin 8− 512  512 0
Linezolid 0.5−21 −2 100
Daptomycin 0.25−21 −2 100
Enterococcus faecium: vancomycin susceptible (n = 427)
Telavancin  0.015−2 0.25 NA (Draghi et al 2006; Sahm 
et al 2006; Jansen et al 
2007)
Vancomycin  0.5−4 1 100
Linezolid  0.015−4 2 97.8−100
Daptomycin  0.015−8 4 98.9−99.3
Enterococcus faecium: vancomycin nonsusceptible (n = 352)
Telavancin  0.015−16 2−8 NA (Draghi et al 2006; Sahm 
et al 2006; Jansen et al 
2007)
Vancomycin 8– 512 512− 512 0
Linezolid 1−16 2 98.8−100
Daptomycin 0.12−82 −4 99.2−100
aTotal number of isolates from all studies evaluated.
bBreakpoints based on Clinical and Laboratory Standards Institute guidelines (CSLI 2007)
Abbreviations: MIC90, minimum inhibitory concentration at which 90% of strains are inhibited; NA, not available for interpretation; NR, not reported.Therapeutics and Clinical Risk Management 2008:4(1) 239
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values are elevated against VanA-type vancomycin-resistant 
enterococci. Like vancomycin, no activity is observed in 
vitro against Gram-negative bacteria. Breakpoints have 
not been established to date. Results from a European 
surveillance study showed that telavancin MICs range 
between 0.06 and 0.5 µg/mL for both MSSA and MRSA 
which was 2- to 4-fold lower than that for vancomycin, 
4- to 80-fold lower than that for linezolid and 2-fold lower 
than that for daptomycin (Jansen et al 2007). Signiﬁ  cantly, 
telavancin demonstrated excellent bactericidal activity 
against isolates of PVL-producing and non-PVL-producing 
CA-MRSA, with MIC and MBC values ranging from 0.25 
to 1 µg/ml (Saravolatz et al 2007). Against 19 isolates of 
staphylococci not susceptible to daptomycin or linezolid, 
telavancin demonstrated MICs ranging from 0.06–1 µg/ml 
(Draghi 2005; Draghi et al 2006). Telavancin also displayed 
excellent activity against VISA derived from clinical isolates 
(MIC90, 1 µg/mL), and was several times more potent than 
vancomycin (MIC90, 8 µg/mL) (Leuthner et al 2006). Indeed, 
telavancin activity against VISA was comparable to or more 
potent than daptomycin and linezolid (MIC90s 1 and 2 µg/mL, 
respectively) (Leuthner et al 2006). In a time-kill study, 
the activity of telavancin was compared in 50 glycopeptide 
non-susceptible staphylococcal strains in the presence and 
absence of serum (Leuthner et al 2006). Included in this 
study were heteroresistant VISA, VISA, and VRSA strains. 
Telavancin demonstrated concentration dependent killing 
at or above 4 times the MIC of each respective strain. The 
telavancin MIC range for VRSAMI, VRSAPA, and VRSANY 
was 1–4 µg/mL (Draghi et al 2005).
Although Staphylococcus epidermidis is a less common 
cause of clinical illness, it is important to note that the in vitro 
MIC values of telavancin are in the range of 0.03–0.5 µg/mL 
for methicillin-sensitive S. epidermidis and 0.25–1 µg/mL for 
methicillin-resistant S. epidermidis. Telavancin retains activity 
against teicoplanin and vancomycin-resistant S. epidermidis 
(Draghi et al 2006; Leuthner et al 2006; Jansen et al 2007). 
This pathogen has assumed a greater role in line and surgical 
site infection in recent years.
Telavancin also has potent activity against species of strep-
tococci, including PRSP with MICs in the 0.02–0.12 µg/mL 
range. MICs for telavancin vs streptococcus were lower than 
those for vancomycin, linezolid and daptomycin. MICs of 
telavancin for non-pneumococcal strains of Streptococcus 
were reported as 0.015–0.12 µg/mL (Jansen et al 2007).
Telavancin has good activity against most strains of 
Gram-positive anaerobes found in cSSSIs like Clostridium 
jeikeium. Likewise, the MIC90 values for telavancin, 
vancomycin, daptomycin and linezolid against C. difﬁ  cile, an 
important super-infection resulting from antibiotic therapy, 
were 0.25, 1, 2, and 8, respectively (Goldstein et al 2004; 
Finegold et al 2005).
Pharmacokinetics
In preclinical studies, pharmacokinetic parameters of 
telavancin were evaluated in mice, rats, dogs and monkeys. 
Tissue distribution was studied in rats and dogs; an in 
vitro assay of microsomal/P450 mediated metabolism was 
performed, and drug – drug interactions were studied in rats. 
Preliminary identiﬁ  cation of metabolites was also determined. 
These studies demonstrated linear kinetics and a modest 
increase in T½ after prolonged dosing at 13 weeks only in the 
rat. Urinary excretion was the primary route of elimination 
with little or no metabolism (Shaw et al 2005).
Most data on the pharmacokinetic proﬁ  le of telavancin 
have been collected in Phase I studies involving 200 
volunteers, including 16 healthy elderly subjects (Duchin 
2004), 16 subjects with moderate hepatic impairment (Wong 
et al 2006) and 22 with varying degrees of renal impairment 
(Duchin et al 2004). The data provided recommendation 
that the therapeutic telavancin dosage in patients with a 
creatinine clearance above 50 mL/min is 10 mg/kg/day. 
Table 2 Effect of dose on pharmacokinetic parameters of telavancin in healthy adult volunteers over 7 days
  Dose
Pharmacokinetic parameters  7.5 mg/kg/day  12.5 mg/kg/day  15 mg/kg/day
Number of subjects  n = 6  n = 6 n  = 4
Cmax (µg/mL) 96.7  ± 19.8  151 ± 17  203 ± 29
AUCss (µg.h/mL) 700  ± 114  1033 ± 91  1165 ± 232
t1/2(h) 8.83  ± 1.71  9.11 ± 2.33  8.78 ± 1.46
Vss (mL/kg)  105 ± 20  119 ± 18  126 ± 15
CL (mL/h/kg)  10.9 ± 1.6  12.2 ± 1.1 13.3  ± 2.6
Phase I study of pharmacokinetic data following 7-day treatment (Shaw et al 2005).
Values were reported as means ± standard deviations.
Abbreviations: AUCss, area under curve at steady state; CL, clearance; Cmax, maximum serum concentration; t1/2, half-life; Vss, volume of distribution at steady state.Therapeutics and Clinical Risk Management 2008:4(1) 240
Dunbar et al
The observed half-life of telavancin at this dosage was 7–9 
hours; plasma concentrations increased in a linear fashion in 
proportion to dose without evidence of clinically signiﬁ  cant 
drug accumulation (Shaw et al 2005). These data further 
support the recommendation for once daily dosing. In a 
study investigating the effect of renal impairment on the 
pharmacokinetics of a single dose of telavancin (Duchin 
et al 2004), a 2- to 3-fold increase in exposure to telavancin 
was found. Thus, for patients with creatinine clearance in 
the range of 30–50 mL/min, a 75% dose (7.5 mg/kg) is 
recommended, and in patients with end-stage renal disease 
and those with a creatinine clearance  30 mL/min, the 
dosing interval should be extended to every 48 hours (Duchin 
et al 2004). In vitro studies have been performed in a model 
of continuous venovenous hemoﬁ  ltration and continuous 
venovenous hemodialysis, but no recommendations for 
dosing in renal failure patients undergoing dialysis were 
proposed (Patel et al 2006a, b). The primary hepatic 
metabolite identiﬁ  ed was a hydroxylated form of the parent 
compound. In a study investigating the effect of moderate 
hepatic impairment on the pharmacokinetics of a single 
dose of telavancin (10 mg/kg), no meaningful differences on 
pharmacokinetics were observed between normal subjects 
and subjects with moderate hepatic impairment (Wong et al 
2006). In a study of pharmacokinetics in subjects 65 years 
and older (Duchin et al 2004), no effect of age was found. 
In laboratory analyses, it was found that telavancin could 
interfere with coagulation assays and with dye tests for 
urinary protein (Laohavaleeson et al 2007).
The concentration of telavancin in tissues that are 
common sites of infection was studied extensively. The 
steady-state AUC in blister ﬂ  uid was 40% of that found in 
plasma but was at a level sufﬁ  cient to eradicate pathogens 
which might be present (Sun et al 2006). In epithelial lining 
ﬂ  uid (ELF), concentrations of telavancin were 10% of that 
in plasma, but levels were 2–8 times higher than the MIC 
of telavancin versus MRSA (Wong et al 2007). In alveolar 
macrophages, levels of telavancin were reported to be higher 
than in ELF and further, in contrast to daptomycin, did not 
seem to be affected by the presence of lung surfactant (Wong 
et al 2007).
Pharmacodynamics
Telavancin pharmacodynamic studies have been conducted in 
several in vitro studies and in vivo animal models of infection. 
The dynamic and static antimicrobial effects of telavancin 
against MRSA and MSSA have been simulated in an in vitro 
kinetic model (Odenholt et al 2007). At a clinically feasible 
area under the curve/MIC ratio of 50, telavancin produced 
  3-log10 killing at 6–8 h postexposure in the absence and 
presence of 50% w/v human plasma. In this study, telavancin 
was the only antibacterial to kill MRSA and MSSA in their 
nongrowing phase (Odenholt et al 2007). In the mouse 
neutropenic thigh (MNT) model, the 24-hour AUC/MIC ratio 
was identiﬁ  ed as the best predictor of efﬁ  cacy (Hegde et al 
2004). Concentration- dependent activity was demonstrated 
against a variety of Gram-positive bacteria, including 
MSSA, MRSA, PSSP, PRSP, and vancomycin-resistant 
Enterococcusfaecalis. In studies of intravenously administered 
telavancin, the effective dose for 50% bactericidal activity 
(ED50) was estimated to range from 0.5 to 6.6 mg/kg with 
pretreatment titers reduced by 3 log CFU/g, supporting 
the bactericidal properties of this molecule. Telavancin, 
vancomycin, and linezolid were also efﬁ  cacious and more 
potent against MRSA in the murine subcutaneous infection 
model (immune system intact) compared with the MNT model. 
This increase in potency was, however, disproportionately 
greater for vancomycin and linezolid when compared to 
telavancin, suggesting that the activity of telavancin is less 
dependent on a competent immune system. In a model of 
MRSA pneumonia, established in immunocompromised mice, 
intravenous or subcutaneously dosed telavancin demonstrated 
superior efﬁ  cacy to intravenous vancomycin and linezolid 
(Reyes et al 2005).
In a model of bacteremia caused by MRSA in immuno-
compromised mice, telavancin was more efﬁ  cacious than 
vancomycin in reducing blood bacterial titers and improving 
survival (Reyes et al 2006). Telavancin was also efﬁ  cacious 
in a rabbit model of aortic valve endocarditis evoked by 
MRSA and VISA (Madrigal et al 2005).
Clinical studies
Two phase II clinical trials were conducted, the FAST and 
FAST 2 studies. Both studies were randomized, double-
blind trials involving centers in the United States and South 
Africa (Stryjewski et al 2005; Stryjewski et al 2006). Both 
studies were conducted to assess safety and explore efﬁ  cacy 
of telavancin in patients with cSSSI. In FAST, a total of 
167 adult patients received either 7.5 mg/kg of telavancin 
intravenously every 24 hours or the standard therapies 
(1 g vancomycin every 12 hours, 0.5–1 g cloxacillin every 6 
hours, or 2 g nafcillin – oxacillin every 6 hours) (Stryjewski 
et al 2005). Dose adjustment of vancomycin was permitted 
based on site-specific guidelines. 84 patients were 
randomized to receive telavancin, while 83 patients received 
the standard therapies. Based upon pre-randomization Therapeutics and Clinical Risk Management 2008:4(1) 241
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choice of the investigator, 75% of those receiving standard 
therapy were given vancomycin, no doubt a reﬂ  ection of 
increased awareness of high prevalence rates of MRSA. 
Drug was given for 7–14 days based on clinical response 
and the investigators judgment. S. aureus was isolated at 
baseline in approximately 50 patients in each treatment 
group, and MRSA was identiﬁ  ed in approximately 50% 
of the S. aureus isolates. Overall cure rates were similar 
at 79% and 80% for telavancin and the standard therapy 
group respectively (p = 0.53). In cases with MRSA, cure 
rates were 82% and 69% for telavancin and the standard 
therapy group, respectively. However, this difference 
was not statistically signiﬁ  cant due to the relatively small 
number of patients involved. In microbiologically evaluable 
patients inclusive of all pathogens, clinical cure rates were 
80% and 82% for telavancin and the standard therapy group 
respectively (p = 0.83).
In FAST 2, the primary goal was to compare the 
efficacy of telavancin dosed at 10 mg/kg intravenously 
every 24 hours with standard therapies (same as in FAST) 
(Stryjewski et al 2006). A total of 195 patients were enrolled 
of which 100 received telavancin. In this study, 93% of the 
standard therapy patients received vancomycin. Among 
the 91 microbiologically evaluable patients with S. aureus 
at baseline, cure rates were 96% and 90% for telavancin 
and the standard therapy group respectively. In the 45 
microbiologically evaluable patients with MRSA at baseline, 
cure rates were also 96% and 90% for telavancin and the 
standard therapy group respectively. In terms of microbiologic 
eradication, telavancin trended towards a better outcome in 
patients with S. aureus than standard therapy (92% vs 78%, 
p = 0.07), but had a statistically signiﬁ  cant better eradication 
rates in patients with MRSA (92% versus 68%, p = 0.04) 
(Stryjewski et al 2006; Drew 2007).
Two large phase III clinical trials, ATLAS I and ATLAS 
II, were completed in mid 2006 comparing telavancin safety 
and efﬁ  cacy to that of vancomycin in patients with cSSSI 
primarily due to MRSA (Corey et al 2006). These studies 
were identical in design and were multinational, randomized, 
and double-blind. Patients were enrolled from 129 sites in 
21 countries. Both studies met the primary efﬁ  cacy endpoint 
of non-inferiority to vancomycin in clinical cure rate at the 
follow-up (test of cure) visit, which occurred 7–14 days after 
the last dose of study medication.
Results from the ATLAS studies have not yet been fully 
published; however preliminary reports state that patients were 
enrolled from 129 sites in 21 countries. Both studies met the 
primary efﬁ  cacy endpoint of non-inferiority to vancomycin 
in clinical cure rate at the follow-up (test of cure) visit, which 
occurred 7–14 days after the last dose of study medication. 
Telavancin-treated patients with cSSSI caused by MRSA 
trended toward an overall better cure rate than vancomycin 
(90.6% versus 86.4%) which was not statistically signiﬁ  cant 
(difference 4.1%, 95% CI, –1.1, 9.3). In addition, telavancin 
showed a higher eradication rate of MRSA than vancomycin 
(89.9% versus 85.4%), which again was not statistically 
signiﬁ  cant (Difference 4.4%, 95%CI, −0.9%, 9.8%) (Corey, 
Stryjewski et al 12–15 October 2006).
Presently, phase III clinical studies are ongoing investi-
gating telavancin in hospital-acquired pneumonia caused by 
Gram-positive bacteria.
Safety and tolerability
Telavancin has generally been well-tolerated in Phase I 
studies of healthy volunteers and in clinical studies involving 
patients with cSSSI (Shaw et al 2005; Corey et al 2006; 
Stryjewski et al 2006). In the phase III ATLAS studies, the 
incidence of adverse events leading to discontinuation of 
treatment was 8% in the telavancin group (n = 928) and 6% 
in the vancomycin group (n = 939) (Corey et al 2006). The 
most common treatment-emergent adverse events associated 
with telavancin were taste alterations (33%), nausea (27%), 
headache and vomiting (both 14%), foamy urine (13%), and 
insomnia and constipation (both 10%) (Corey et al 2006). 
In the FAST 2 study, increases in serum creatinine from 
normal to abnormal were more frequent in patients receiving 
telavancin than vancomycin (5 of 100 patients vs 0 of 95 
patients) (Stryjewski et al 2006). Maximum concentrations of 
serum creatinine were  1.8 mg/dL in all but one telavancin 
patient, and creatinine values returned to the normal range 
for this patient during follow-up. In a separate safety study, at 
higher doses, some vomiting and the infusion-related reaction 
previously described with vancomycin therapy, known 
as “red-man syndrome”, occurred in a small percentage 
of telavancin recipients (Barriere et al 2004). A clinically 
insigniﬁ  cant prolongation of the QTc was noted in healthy 
volunteers ( 5 msec) and did not appear to be dose related 
(Barriere et al 2004). In particular, no telavancin recipients 
in this study had a prolonged prolonged QTcF of  500 msec 
or any abnormal U-waves (Barriere et al 2004). In ATLAS 
(Corey et al 2006), electrocardiogram analyses identiﬁ  ed 
a prolonged QTcF of  500 msec in 1 telavancin patient 
and 2 vancomycin patients and prolonged QTc interval 
by  60 msec in 10 telavancin patients (1%) and 5 vancomycin 
patients (0.5%). None of these ECG abnormalities were 
associated with cardiac events.Therapeutics and Clinical Risk Management 2008:4(1) 242
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Conclusions
Studies to date have shown that telavancin, a new lipogly-
copeptide antibiotic that is a semi-synthetic derivative of 
vancomycin, has rapid bactericidal activity against a variety 
of clinically important Gram-positive pathogens known to 
be the predominant causative bacteria in cSSSIs. Overall 
outcome in studies using extended spectrum penicillins or 
vancomycin as the comparator agents versus telavancin 
have demonstrated comparable clinical outcomes. In the 
subset of patients infected with MRSA, results in a phase 
II study have shown a statistically signiﬁ  cant better out-
come in the telavancin treated patients (Laohavaleeson 
et al 2007). There was a similar trend, although not statisti-
cally signiﬁ  cant in the phase III trials. In vitro studies have 
demonstrated excellent activity against multi-drug resistant 
strains including MRSA, PRSP, heteroresistant VISA, VISA, 
and VRSA (Laohavaleeson et al 2007). Data from animal 
models of infection support the bactericidal properties of 
telavancin. Adverse events associated with telavancin treat-
ment have been largely mild to moderate in severity, and 
except for nausea, vomiting, taste disturbance, and foamy 
urine, occurred at similar frequencies to that of comparator 
drugs in phase II and III studies. Laboratory abnormalities 
of signiﬁ  cance include increased serum creatinine (largely 
low-grade), occurring in a small proportion of patients. Serum 
creatinine returned to baseline following discontinuation of 
drug (Stryjewski et al 2006). The work referenced in this 
summary of telavancin supports its safety and effectiveness 
in the treatment of cSSSIs. With FDA approval and that of 
worldwide regulatory agencies, it will provide an important 
new option in the treatment of serious infections caused by 
Gram-positive bacteria, especially those bacteria resistant to 
many of the currently available agents.
Expert opinion
Although the problem of resistant strains of Gram-positive 
organisms was initially largely conﬁ  ned to the in-hospital 
setting, the eruption of CA-MRSA strains and the increasing 
prevalence of strains heteroresistant to vancomycin have led to 
considerable concern in the management of serious infections 
likely to be caused by these pathogens. The virulence of the 
community-acquired strain has resulted in an unprecedented 
number of patients appearing in emergency departments 
across the United States with large abscesses surrounded 
by extensive cellulitic changes, frequently in the setting of 
no known disruption in the integrity of the skin. Hence the 
well known “must have been a spider bite” complaint has 
emerged as a risk factor for CA-MRSA (Moran et al 2006). 
Clindamycin, trimethoprim-sulfamethoxazole, and the 
tetracyclines are ﬁ  rst-line therapies for use in the treatment of 
these infections, especially in the outpatient setting. However, 
there are no controlled clinical trials to support their efﬁ  cacy 
and it is unlikely that such studies will be done since these 
agents are all now generic drugs. Unlike cSSSIs caused by 
CA-MRSA, those by HA-MRSA are often recalcitrant. As the 
distinction between cSSSIs due to CA-MRSA and HA-MRSA 
becomes blurred, it is increasingly difﬁ  cult for clinicians to 
rely on traditional agents as empirical therapy. Given that 
the development of intermediate and frank resistant strains 
of S. aureus to vancomycin has led to clinical failures, it is 
imperative that more effective agents become available. In this 
regard, telavancin shows promise as an excellent choice for the 
management of cSSSI though its place relative to traditional 
and developmental agents will ultimately be decided by results 
from ongoing preclinical, clinical and economic studies. 
Each of the agents currently in development for cSSSI are 
associated with speciﬁ  c advantages and limitations relative 
to vancomycin. For example, the long elimination half-life of 
dalbavancin appears to offer the opportunity for a once-weekly 
dosing strategy on an outpatient basis, but this pharmacokinetic 
may also be a problem since any dalbavancin-associated 
adverse effects are likely to be enduring. The development 
of ceftobirole and iclaprim is welcomed, as these agents are 
derived from parent molecules with a traditionally good safety 
proﬁ  le; however, both agents possess a solitary mechanism 
of action that may increase the chance of rapid resistance 
development if used empirically.
As referenced in the body of this paper, telavancin clinical 
efﬁ  cacy, microbiological eradication, and safety have been 
demonstrated for a variety of Gram-positive infections, 
including those caused by resistant strains of S. aureus and 
S. pneumonia. Its multifunctional, cidal mode of action confers 
an extremely low potential for resistance development while its 
once-daily dosing regimen lends itself to use in the outpatient 
setting. In light of the added expense of in-hospital care and 
the pressure to limit the duration of hospital stays, an economic 
study has been established to determine the exact cost savings 
relative to vancomycin. Release of the PVL toxin is a major 
concern in serious necrotizing infections. Important studies are 
currently investigating the bactericidal activity of telavancin. If 
the ﬁ  ndings determine that telavancin does not induce prokary-
otic cell lysis, then by inference, telavancin therapy may mini-
mize release of preformed PVL toxin. Its rapidly bactericidal 
activity likewise may possibly further reduce production of 
this toxin. No doubt this information will add to the clinician’s 
comfort in use of this agent in serious infections.Therapeutics and Clinical Risk Management 2008:4(1) 243
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